firocoxib has been researched along with cj-023,423 in 1 studies
| Studies (firocoxib) | Trials (firocoxib) | Recent Studies (post-2010) (firocoxib) | Studies (cj-023,423) | Trials (cj-023,423) | Recent Studies (post-2010) (cj-023,423) |
|---|---|---|---|---|---|
| 102 | 43 | 71 | 31 | 9 | 28 |
| Protein | Taxonomy | firocoxib (IC50) | cj-023,423 (IC50) |
|---|---|---|---|
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | 0.181 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beugnet, F; de Salazar Alcalá, AG; Dehman, A; Gioda, L | 1 |
1 trial(s) available for firocoxib and cj-023,423
| Article | Year |
|---|---|
Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Dog Diseases; Dogs; Lameness, Animal; Random Allocation; Sulfones; Sulfonylurea Compounds; Uric Acid | 2019 |